Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
gptkb:205923-56-4
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2015)
|
| gptkbp:compatibleWith |
gptkb:FDA
gptkb:EMA |
| gptkbp:developedBy |
gptkb:Immunomedics
|
| https://www.w3.org/2000/01/rdf-schema#label |
epratuzumab
|
| gptkbp:macromoleculeType |
gptkb:B_cells
|
| gptkbp:mechanismOfAction |
binds to CD22 on B cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
IMMU-103
|
| gptkbp:target |
gptkb:CD22
|
| gptkbp:type |
humanized monoclonal antibody
|
| gptkbp:UNII |
6O6F6OQK0E
|
| gptkbp:usedFor |
gptkb:systemic_lupus_erythematosus
|
| gptkbp:bfsParent |
gptkb:CD22
|
| gptkbp:bfsLayer |
7
|